Shots:

• The P-III DUO study involves assessing of Copiktra (Duvelisib) vs ofatumumab in 319 patients with r/r CLL (n=312)/SLL (n=7) after at least two prior therapies in ratio 1:1
• The P-III study results: ORR (78% vs 39%); PFS (16.4mos. vs 9.1 mos.); presented at 23rd Annual International Congress on Hematologic Malignancies
• Copiktra(25mg- q2d) is an oral inhibitor of PI3Ki (phosphoinositide 3-kinase)- first approved dual inhibitor of PI3K-delta and PI3K-gamma. On 24 Sept-2018- Copiktra received FDA’s approval for r/r CLL/SLL and accelerated approval for r/r follicular lymphoma (FL)

Ref: Verastem Oncology | Image: Verastem Oncology